FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2937536762> ?p ?o ?g. }

• W2937536762 endingPage "10" @default.
• W2937536762 startingPage "3" @default.
• W2937536762 abstract "The role of elective whole-pelvis radiotherapy (WPRT) remains controversial. Few studies have investigated it in Gleason grade group (GG) 5 prostate cancer (PCa), known to have a high risk of nodal metastases. To assess the impact of WPRT on patients with GG 5 PCa treated with external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT + BT). We identified 1170 patients with biopsy-proven GG 5 PCa from 11 centers in the United States and one in Norway treated between 2000 and 2013 (734 with EBRT and 436 with EBRT + BT). Biochemical recurrence-free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific survival (PCSS) were compared using Cox proportional hazards models with propensity score adjustment. A total of 299 EBRT patients (41%) and 320 EBRT + BT patients (73%) received WPRT. The adjusted 5-yr bRFS rates with WPRT in the EBRT and EBRT + BT groups were 66% and 88%, respectively. Without WPRT, these rates for the EBRT and EBRT + BT groups were 58% and 78%, respectively. The median follow-up was 5.6 yr. WPRT was associated with improved bRFS among patients treated with EBRT + BT (hazard ratio [HR] 0.5, 95% confidence interval [CI] 0.2–0.9, p = 0.02), but no evidence for improvement was found in those treated with EBRT (HR 0.8, 95% CI 0.6–1.2, p = 0.4). WPRT was not significantly associated with improved DMFS or PCSS in the EBRT group (HR 1.1, 95% CI 0.7–1.7, p = 0.8 for DMFS and HR 0.7, 95% CI 0.4–1.1, p = 0.1 for PCSS), or in the EBRT + BT group (HR 0.6, 95% CI 0.3–1.4, p = 0.2 for DMFS and HR 0.5 95% CI 0.2–1.2, p = 0.1 for PCSS). WPRT was not associated with improved PCSS or DMFS in patients with GG 5 PCa who received either EBRT or EBRT + BT. However, WPRT was associated with a significant improvement in bRFS among patients receiving EBRT + BT. Strategies to optimize WPRT, potentially with the use of advanced imaging techniques to identify occult nodal disease, are warranted. When men with a high Gleason grade prostate cancer receive radiation with external radiation and brachytherapy, the addition of radiation to the pelvis results in a longer duration of prostate-specific antigen control. However, we did not find a difference in their survival from prostate cancer or in their survival without metastatic disease. We also did not find a benefit for radiation to the pelvis in men who received radiation without brachytherapy." @default.
• W2937536762 created "2019-04-25" @default.
• W2937536762 creator A5001069772 @default.
• W2937536762 creator A5002414848 @default.
• W2937536762 creator A5004874300 @default.
• W2937536762 creator A5004893863 @default.
• W2937536762 creator A5008857530 @default.
• W2937536762 creator A5012794522 @default.
• W2937536762 creator A5014122459 @default.
• W2937536762 creator A5015096941 @default.
• W2937536762 creator A5015241404 @default.
• W2937536762 creator A5015974298 @default.
• W2937536762 creator A5017059128 @default.
• W2937536762 creator A5020281769 @default.
• W2937536762 creator A5023026845 @default.
• W2937536762 creator A5024098067 @default.
• W2937536762 creator A5037174103 @default.
• W2937536762 creator A5039646183 @default.
• W2937536762 creator A5040778833 @default.
• W2937536762 creator A5041615709 @default.
• W2937536762 creator A5044514299 @default.
• W2937536762 creator A5046389074 @default.
• W2937536762 creator A5046420649 @default.
• W2937536762 creator A5046657217 @default.
• W2937536762 creator A5049646055 @default.
• W2937536762 creator A5054386630 @default.
• W2937536762 creator A5055949265 @default.
• W2937536762 creator A5060371062 @default.
• W2937536762 creator A5061374420 @default.
• W2937536762 creator A5066038909 @default.
• W2937536762 creator A5066513804 @default.
• W2937536762 creator A5066698252 @default.
• W2937536762 creator A5068005365 @default.
• W2937536762 creator A5070623757 @default.
• W2937536762 creator A5075260710 @default.
• W2937536762 creator A5075740763 @default.
• W2937536762 creator A5076238068 @default.
• W2937536762 creator A5077333954 @default.
• W2937536762 creator A5081839864 @default.
• W2937536762 creator A5083115147 @default.
• W2937536762 creator A5087591232 @default.
• W2937536762 creator A5088927067 @default.
• W2937536762 creator A5089858828 @default.
• W2937536762 date "2020-01-01" @default.
• W2937536762 modified "2023-10-16" @default.
• W2937536762 title "Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis" @default.
• W2937536762 cites W1503328597 @default.
• W2937536762 cites W1966714873 @default.
• W2937536762 cites W1977970364 @default.
• W2937536762 cites W2004601306 @default.
• W2937536762 cites W2011197894 @default.
• W2937536762 cites W2013749950 @default.
• W2937536762 cites W2021220421 @default.
• W2937536762 cites W2025813238 @default.
• W2937536762 cites W2039003059 @default.
• W2937536762 cites W2054899405 @default.
• W2937536762 cites W2063931072 @default.
• W2937536762 cites W2066558158 @default.
• W2937536762 cites W2068325458 @default.
• W2937536762 cites W2074796455 @default.
• W2937536762 cites W2093867637 @default.
• W2937536762 cites W2098733695 @default.
• W2937536762 cites W2102252264 @default.
• W2937536762 cites W2112681257 @default.
• W2937536762 cites W2115590169 @default.
• W2937536762 cites W2116312562 @default.
• W2937536762 cites W2131809909 @default.
• W2937536762 cites W2147437793 @default.
• W2937536762 cites W2149659669 @default.
• W2937536762 cites W2167949509 @default.
• W2937536762 cites W2502183409 @default.
• W2937536762 cites W2536173378 @default.
• W2937536762 cites W2746784295 @default.
• W2937536762 cites W2756437663 @default.
• W2937536762 cites W2789775641 @default.
• W2937536762 cites W2797344377 @default.
• W2937536762 cites W2896978422 @default.
• W2937536762 cites W4239728164 @default.
• W2937536762 doi "https://doi.org/10.1016/j.eururo.2019.03.022" @default.
• W2937536762 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7521828" @default.
• W2937536762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30992160" @default.
• W2937536762 hasPublicationYear "2020" @default.
• W2937536762 type Work @default.
• W2937536762 sameAs 2937536762 @default.
• W2937536762 citedByCount "18" @default.
• W2937536762 countsByYear W29375367622020 @default.
• W2937536762 countsByYear W29375367622021 @default.
• W2937536762 countsByYear W29375367622022 @default.
• W2937536762 countsByYear W29375367622023 @default.
• W2937536762 crossrefType "journal-article" @default.
• W2937536762 hasAuthorship W2937536762A5001069772 @default.
• W2937536762 hasAuthorship W2937536762A5002414848 @default.
• W2937536762 hasAuthorship W2937536762A5004874300 @default.
• W2937536762 hasAuthorship W2937536762A5004893863 @default.
• W2937536762 hasAuthorship W2937536762A5008857530 @default.
• W2937536762 hasAuthorship W2937536762A5012794522 @default.
• W2937536762 hasAuthorship W2937536762A5014122459 @default.
• W2937536762 hasAuthorship W2937536762A5015096941 @default.

• next